Status:
COMPLETED
Sugammadex and Heart Failure
Lead Sponsor:
Onze Lieve Vrouw Hospital
Conditions:
Postoperative Neuromuscular Block
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Although anticholinesterase reversal agents have been used in combination with anticholinergic drugs for over half a century, it has been suggested that they should be used with caution in patients wi...
Eligibility Criteria
Inclusion
- aged 18 yr or older
- categorized as American Society of Anesthesiologists class 3-4 and New York Heart Association class 2-4
- with an ejection fraction \<25%
- scheduled to undergo elective surgery for cardiac resynchronization therapy, an automated implantable cardioverter-defibrillator (ICD), or battery replacement of an ICD or biventricular pacemaker, during general anaesthesia.
Exclusion
- expected to have a difficult intubation for anatomic reasons
- they had a neuromuscular disorder
- a personal or family history of malignant hyperthermia
- or known allergy to medication used during general anaesthesia
- not able or willing to give written informed consent.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01509651
Start Date
January 1 2012
End Date
April 1 2012
Last Update
April 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OLV Hospital
Aalst, Belgium, 9300